Critical Gaps in Genetic Cancer Risk Testing Revealed by Recent Study

A recent comprehensive study highlights significant shortcomings in the testing of patients with womb cancer for genetic conditions that may put them at risk of additional cancers. Published in the journal BMJ Oncology, the research investigates the extent of genetic testing and follow-up procedures in the UK and Ireland. Despite clear guidelines from the NHS recommending that all patients with womb or bowel cancer undergo tumor testing for Lynch syndrome—a hereditary condition increasing the likelihood of womb and bowel cancers—less than half of eligible women actually received a blood test to confirm this diagnosis.

Lynch syndrome affects approximately 1 in 300 people and is caused by small genetic variations similar to those seen in BRCA-related breast cancer risk. Women with this syndrome have a 50% chance of developing womb cancer during their lifetime, compared to a 3% risk in the general population. Identifying this condition is crucial because it enables preventive measures, such as lifestyle modifications, regular screenings, or preventative surgeries, which can significantly reduce future cancer risks. It also has implications for family members who may unknowingly carry the genetic variant.

The study analyzed over 2,500 cases of womb cancer and found that although 91% of tumors were tested for Lynch syndrome markers, the results often were not communicated effectively to the broader clinical teams. Consequently, many patients did not receive necessary follow-up tests or genetic counseling. Only 48% of women who should have undergone further testing actually received a blood test. This gap in the testing process leaves many individuals undiagnosed, risking subsequent development of bowel cancer and depriving family members of vital preventive opportunities.

Experts emphasize that early detection through proper testing could enable interventions such as taking aspirin or undergoing regular colonoscopies to prevent bowel cancer, or hysterectomies to prevent recurrence of womb cancer. The study underscores the need to streamline and make more accessible the process of genetic testing so that more women with Lynch syndrome can be diagnosed and managed effectively. The research was led by Dr. Neil Ryan of the University of Edinburgh and coordinated by the UK Audit and Research Collaborative in Obstetrics and Gynaecology (UK ARCOG). Dr. Ryan states, "Despite high tumor testing rates, many women with Lynch syndrome remain undiagnosed due to delays and suboptimal referral for blood testing. Making genetic testing truly mainstream is essential for improving patient outcomes and family health."

This finding calls for urgent action to address gaps in genetic testing pathways, ensuring timely and comprehensive screening for at-risk women, ultimately reducing future cancer burdens and safeguarding families.